|
Aug 6
|
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
|
|
Aug 5
|
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 5
|
Esperion Therapeutics: Q2 Earnings Snapshot
|
|
Aug 5
|
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 31
|
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
|
|
Jul 30
|
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
|
|
Jul 29
|
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 29
|
Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors
|
|
Jul 22
|
Esperion to Report Second Quarter 2025 Financial Results on August 5
|
|
Jul 17
|
What’s the Status on Digital Product Passport Implementation?
|
|
Jul 1
|
Esperion Appoints Craig Thompson to Board of Directors
|
|
Apr 23
|
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
|
|
Apr 23
|
Esperion to Report First Quarter 2025 Financial Results on May 6
|
|
Apr 22
|
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Apr 21
|
Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
|
|
Feb 18
|
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
|
|
Jan 2
|
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
|
|
Nov 26
|
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
|
|
Oct 3
|
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
|
|
Oct 2
|
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
|